HBsAg Positive: What Happens Next

01

Does one positive HBsAg mean I have hepatitis B?

It means hepatitis B virus is present, and the next questions are for how long and with what effect. HBsAg is a protein on the surface of the virus that can be detected at high levels in serum during acute or chronic infection. On its own it does not tell you whether this is a recent infection that will clear, or a long-standing one, and it says nothing yet about whether your liver has been harmed. That is what the rest of the panel is for.

It is also worth knowing that testing is now routine rather than a sign that something was suspected about you. CDC recommends screening all adults aged 18 and older for hepatitis B at least once in their lifetime using a triple panel test, and screening for HBsAg in all pregnant women during each pregnancy, preferably in the first trimester, regardless of vaccination status or previous testing. Many people learn they are positive through exactly that route, feeling entirely well. Globally, hepatitis B is a large and under-treated problem: WHO counted 240 million people living with chronic infection in 2024, of whom 65 million, or 27%, were aware of their status.

02

Which tests come next, and what each one tells

The triple panel is the starting set: HBsAg, antibody to hepatitis B surface antigen (anti-HBs) and total antibody to hepatitis B core antigen (total anti-HBc). Each answers a different question. HBsAg says the virus is present. Anti-HBs is generally interpreted as indicating recovery and immunity from infection, and is also what a vaccine produces. Total anti-HBc appears at the onset of symptoms in acute hepatitis B and then persists for life, which makes it the marker that distinguishes someone who has met the virus from someone who has only met the vaccine.

A fourth marker sorts out timing. IgM anti-HBc positivity indicates recent infection with the virus, within less than six months. So the combination of HBsAg positive with total anti-HBc positive and IgM anti-HBc positive points to acute infection, while HBsAg positive with total anti-HBc positive and IgM anti-HBc negative points to chronic infection. Two other patterns are common and often misread: HBsAg negative with total anti-HBc and anti-HBs positive is resolved past infection, and HBsAg negative with anti-HBs positive but total anti-HBc negative is immunity from vaccination.

Beyond serology, the assessment moves to the liver itself. WHO's 2024 guidance uses ALT levels, AST for calculating an APRI score, and HBV DNA where the test is available, to decide who needs treatment. APRI is worked out from routine blood results rather than from a biopsy, which is precisely why it is used: it lets the decision be made in an ordinary clinic. Where elastography is available, a liver stiffness measurement is used alongside it.

03

Acute or chronic: how is that decided?

By time, and by IgM anti-HBc. Acute hepatitis B is a short-term illness occurring within the first six months after exposure to the virus, and acute infection can either resolve or become lifelong. Symptoms of acute infection, when they occur, include yellowing of the skin and eyes, dark urine, feeling very tired, nausea, vomiting and abdominal pain, and severe cases can progress to liver failure. Most newly infected people have no symptoms at all, which is why the date of infection is often unknown.

Age at infection decides the odds more than anything else. WHO puts the risk of chronic hepatitis after infection in infancy and early childhood at about 95%, and its 2024 guidelines break that down further: about 90% of those infected as newborns, about 30% of children infected between one and four years of age. Infection acquired in adulthood leads to chronic hepatitis in less than 5% of cases. For an adult who has just tested positive after a recent exposure, that is genuinely reassuring information, and it is the reason a repeat test months later matters: many adults clear the surface antigen. But that comfort belongs to an adult with a known recent exposure and an illness to date it by. If you have no idea when you could have been infected, do not assume it was recent: most people infected as babies or small children never had a symptom, and a positive test turning up at a routine screen is far more often long-standing than new. The IgM anti-HBc result, not the assumption, tells you which one you are, and it is worth having before anyone settles on waiting to see. For someone likely infected at birth or in early childhood, chronic infection is the expected finding rather than a surprise.

The practical answer is to avoid deciding on one blood sample. A positive HBsAg with a negative IgM anti-HBc in a person who has been well for years is chronic infection, and the assessment moves straight to liver status. A positive HBsAg during an acute illness needs the follow-up test before anyone concludes anything permanent. Ask specifically when the repeat should be done and put the date in your phone.

04

What HBeAg, anti-HBe and HBV DNA add

HBV DNA measures how much virus is actually circulating, and it is the number that most directly drives treatment decisions. WHO recommends treatment for people with chronic infection who have an HBV DNA above 2000 IU/mL together with an ALT above the upper limit of normal, defined as 30 U/L for men and boys and 19 U/L for women and girls. Those ALT limits are lower than the reference ranges printed on many laboratory reports, which is one reason people have been told for years that their liver tests were normal.

HBeAg and anti-HBe describe the phase of the infection. Loss of HBeAg with the appearance of anti-HBe, known as seroconversion, reflects spontaneous improvement with a decline in viral replication and normalisation of ALT, and confers a good prognosis. It is a change worth knowing about, but it is not an all-clear: WHO's monitoring recommendations still include HBsAg and HBeAg or anti-HBe testing as part of ongoing assessment, alongside ALT, HBV DNA and a fibrosis score. Loss of HBsAg itself is the best outcome and occurs rarely.

Where HBV DNA testing is not available, the 2024 guidance deliberately does not leave people stranded. Persistently abnormal ALT levels, defined as two ALT values above the upper limit of normal during a 6- to 12-month period, are a treatment indication regardless of the APRI score, as a conditional recommendation. That change matters most in exactly the settings where viral load testing is hardest to obtain.

05

Is "carrier" still a real category?

The word is best retired, because of what people hear in it. "Carrier" was widely used to mean someone who had the virus but needed nothing done, and that conclusion is now wrong far more often than it used to be. WHO's 2024 guidance expanded and simplified who should be treated, and recommends treatment for people with chronic hepatitis B and significant fibrosis, defined by an APRI score above 0.5 or a transient elastography value above 7 kPa, regardless of HBV DNA or ALT levels. Someone previously labelled a carrier may sit in that group without ever having had a symptom.

The list of people who should be treated regardless of fibrosis stage, viral load or ALT is longer than many clinics realise. It includes people coinfected with HIV, hepatitis D or hepatitis C; people with a family history of liver cancer or cirrhosis; people with immune suppression, such as long-term steroids or a solid organ or stem cell transplant; people with comorbidities including diabetes and metabolic dysfunction-associated steatotic liver disease; and people with extrahepatic manifestations such as glomerulonephritis or vasculitis. A family history of liver cancer alone changes the plan.

The honest replacement for "carrier" is longer and less comfortable: chronic hepatitis B, not currently meeting treatment criteria, to be reassessed on a schedule. It is accurate, and it makes clear that the status is provisional rather than a label you have been given for life. ALT and HBV DNA fluctuate over years, and a person can move in and out of the treatment groups without noticing anything. That is why the follow-up interval, not the word on the old report, is the part to hold on to.

06

Treatment or monitoring - and how often?

If you do not meet treatment criteria, the recommendation is monitoring at least annually for disease progression, with ALT and, where the test is available, HBV DNA. The fuller panel, adding AST for the APRI score along with HBsAg and HBeAg or anti-HBe, is what WHO recommends at least annually for people who are on treatment. Fluctuating or persistently raised ALT with an HBV DNA above 2000 IU/mL is the pattern that indicates progressive disease and the need for treatment, so it is a reason to be reassessed rather than to wait for next year. Annual is a floor, not a ceiling, and missing years is how cirrhosis is found late.

If you do meet the criteria, treatment is antiviral medication taken by mouth, at the dose your doctor sets, and it is usually long-term: most people who start hepatitis B treatment must continue it for life. What treatment is understood to do is slow the advance of cirrhosis, reduce cases of liver cancer and improve long-term survival. It does not eliminate the virus from the body, and stopping it, or leaving long gaps in it, without medical advice is not a neutral act; the decision to stop belongs to the doctor who started it. People on treatment are also monitored at least annually, more often in the first year if disease is advanced or adherence is a concern.

Globally the gap is not in the science but in the follow-through: of the people estimated to be living with chronic hepatitis B in 2024, only about 4.3% were receiving antiviral treatment. If you have been told you are positive and have had no appointment since, that is the single most useful thing to fix. Ask for the next test date in writing rather than waiting to be called.

07

What my family and partner should do now

They should be tested, and then vaccinated if they are not already immune. CDC lists household contacts or former household contacts of people with known hepatitis B infection, and people who have shared needles with or had sexual contact with someone with known infection, among those who should be tested. Testing first matters, because the triple panel distinguishes three different situations - already immune, already infected, or susceptible - and each leads somewhere different.

Vaccination covers the susceptible. CDC recommends hepatitis B vaccination for all infants, for children and adolescents under 19 who were not previously vaccinated, for all adults aged 19 through 59, and for adults aged 60 and older who are at higher risk. A partner or housemate of someone with hepatitis B falls squarely into that higher-risk group. The vaccine protects the people around you far more reliably than any change in household habits does.

There is one group that needs more than a conversation. All infants born to people who are HBsAg positive should be tested for HBsAg and anti-HBs, and every baby should receive the first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by the remaining doses of the series. If there is a pregnancy in the household, that is the item to raise at the next antenatal visit rather than at the delivery.

08

Pregnancy, work and sharing food: what actually transmits it

Hepatitis B is transmitted when blood, semen or another body fluid from an infected person enters the body of someone uninfected. It is not spread through kissing or sharing utensils, and it is also not spread through sneezing, coughing, hugging, breastfeeding, or food or water. That sentence is worth reading twice, because the fear of it is what costs people jobs, marriages and places at the family table. A positive result is a reason to be assessed and followed up, and not a reason to give up any of those things. Most people who test positive feel entirely well, and what changes the long view is being monitored and treated when the criteria are met. Our separate story on how hepatitis B spreads goes through the casual-contact question in more detail.

Pregnancy is where the 2024 guidance changed most. Where HBV DNA or HBeAg testing is available, tenofovir disoproxil fumarate prophylaxis is recommended for all HBsAg-positive pregnant women with an HBV DNA of 200 000 IU/mL or more or a positive HBeAg, preferably from the second trimester until at least delivery or completion of the infant vaccination series. Where that testing is not available, the new conditional recommendation is that prophylaxis may be considered for all HBsAg-positive pregnant women, again preferably from the second trimester until at least delivery.

All of this sits on top of the vaccine, not instead of it. Every intervention in pregnancy is given in addition to at least three doses of hepatitis B vaccination for all infants, including a timely birth dose. For work and daily life, the practical measures are the ordinary ones: do not share razors, toothbrushes or needles, cover cuts, and make sure tattooing or piercing is done with sterile equipment. Nothing about your cooking, your cutlery or your presence in a shared office needs to change.